- Home
- NBBK vs INBX Comparison
NBBK vs INBX Comparison
Compare NBBK & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBBK | INBX |
|---|---|---|
| Founded | 1892 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 889.5M | 999.7M |
| IPO Year | 2023 | 2024 |
Fundamental Metrics
Financial Performance| Metric | NBBK | INBX |
|---|---|---|
| Price | $19.94 | $128.07 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $23.50 | ★ $150.00 |
| AVG Volume (30 Days) | 323.3K | ★ 431.1K |
| Earning Date | 04-22-2026 | 05-15-2026 |
| Dividend Yield | ★ 1.43% | N/A |
| EPS Growth | ★ 25.23 | N/A |
| EPS | ★ 1.34 | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | $45.15 | N/A |
| Revenue Next Year | $4.18 | N/A |
| P/E Ratio | $14.67 | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $15.44 | $10.90 |
| 52 Week High | $22.86 | $155.29 |
Technical Indicators
Market Signals| Indicator | NBBK | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 39.73 | 77.15 |
| Support Level | $19.87 | $69.30 |
| Resistance Level | $20.63 | $155.29 |
| Average True Range (ATR) | 0.59 | 11.17 |
| MACD | -0.24 | 3.85 |
| Stochastic Oscillator | 33.33 | 66.82 |
Price Performance
Historical ComparisonAbout NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. The group's business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, consumer loans, and other related services.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.